Whether baclofen is still indicated for the treatment of alcohol consumption disorders is still being debated in addiction medicine expert groups, given conflicting results regarding its efficacy. We summarize current knowledge about self-addiction with focused baclofen and provide an overview of reliable scientific evidence for treatment of such addiction. Therefore, the risk of attempting suicide with baclofen appears real. Numerous studies have shown that patients given baclofen in doses greater than 80 mg per day are more likely than others to attempt suicide. Central nervous system depression is common after ingestion of large doses of baclofen. Seizures require admission to the ICU and should be treated like any other toxicological seizure. Cardiac complications include QTc interval prolongation, severe heart block, premature atrial contraction, supraventricular tachycardia, hypotension, and bradycardia. For poisoning, the elimination half-life of baclofen can last 12 to 36 hours after an overdose, and renal failure is known to delay its clearance. Although rarely measured in clinical practice, baclofen blood concentration toxicity values ​​range from 1.1 to 3.5 mg/l, with coma or fatal intoxication observed at 6 to 9.6 mg/l. Although baclofen withdrawal symptoms have been observed, baclofen intoxication and baclofen withdrawal symptoms share many clinical features, making the diagnosis of withdrawal symptoms difficult when autointoxication is suspected. Hospitalization for treatment of attempted suicide with baclofen is mandatory and should not be limited to baclofen alone. It should include other aspects of holistic care for patients with alcohol disorders: psychological and psychosocial interventions, treatment of comorbid mental illness and physical complications. Baclofen is widely used to treat spasticity associated with neuropathy due to its muscle relaxant effect. It acts on gamma-aminobutyric acid (GABA)-B receptors in the spinal cord and is used to treat muscle spasms associated with spinal cord disease or injury. Since 2002, many medical teams have investigated the use of baclofen in treating alcoholics. Conflicting results have been observed in double-blind, randomized clinical trials (RCTs) conducted to evaluate efficacy at both low doses of baclofen. Nevertheless, recent RCTs have failed to demonstrate that baclofen is superior with respect to long-term follow-up at such high doses. However, guidelines or evidence for prescribing baclofen for this indication are still lacking. Baclofen is now being increasingly prescribed in both low and high doses, especially in European countries. With the increase in prescriptions, there are more and more cases of self-intoxication with baclofen. In France, since 2008, the use of high-dose baclofen (HDB), i.H. This has caused controversy among experts, especially regarding the increased risk of suicide attempts. As baclofen use becomes more widespread, the potential for intentional and unintentional exposure increases. Literature evidence suggests that the effects of baclofen overdose are usually severe and require admission to an intensive care unit. Seizures, cardiac arrests, and deaths have been reported. Given this conflicting information, we conducted a systematic literature review on baclofen overdose, focusing on patients with alcohol use disorder (AUD). Baclofen, a commonly prescribed muscle relaxant, is excreted primarily by the kidneys. Toxicity can be a serious side effect for patients with renal impairment. We describe a patient with end-stage renal disease who developed neurotoxicity and hemodynamic instability after undergoing hemodialysis and receiving baclofen for muscle spasms.